Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.
Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, Cartolano M, Oberbeck S, Mayer P, Berg V, Thomalla D, Kutsch N, Stiefelhagen M, Cramer P, Wendtner CM, Persigehl T, Saleh A, Altmüller J, Nürnberg P, Pallasch C, Achter V, Lang U, Eichhorst B, Castiglione R, Schäfer SC, Büttner R, Kreuzer KA, Reinhardt HC, Hallek M, Frenzel LP, Peifer M. Herling CD, et al. Among authors: weiss j. Nat Commun. 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7. Nat Commun. 2018. PMID: 29463802 Free PMC article. Clinical Trial.
Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.
Pasternack H, Fassunke J, Plum PS, Chon SH, Hescheler DA, Gassa A, Merkelbach-Bruse S, Bruns CJ, Perner S, Hallek M, Büttner R, Bollschweiler E, Hölscher AH, Quaas A, Zander T, Weiss J, Alakus H. Pasternack H, et al. Among authors: weiss j. Sci Rep. 2018 Oct 8;8(1):14941. doi: 10.1038/s41598-018-33027-4. Sci Rep. 2018. PMID: 30297788 Free PMC article.
Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
Gassa A, Fassunke J, Schueten S, Kuhlmann L, Scherer M, Qien J, Zhao Y, Michel M, Loeser H, Wolf J, Buettner R, Doerr F, Heldwein M, Hagmeyer L, Frank K, Merkelbach-Bruse S, Quaas A, Bruns C, Hekmat K, Weiss J, Wahlers T, Alakus H. Gassa A, et al. Among authors: weiss j. Lung Cancer. 2021 Jan;151:91-96. doi: 10.1016/j.lungcan.2020.10.019. Epub 2020 Nov 5. Lung Cancer. 2021. PMID: 33257044 Free article.
B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
Fürstenau M, Fink AM, Schilhabel A, Weiss J, Robrecht S, Eckert R, de la Serna J, Crespo M, Coscia M, Vitale C, Böttcher S, Weppner G, Ritgen M, Stilgenbauer S, Tausch E, Fischer K, Hallek M, Eichhorst B, Brüggemann M, Herling CD. Fürstenau M, et al. Among authors: weiss j. Blood. 2021 Apr 22;137(16):2267-2271. doi: 10.1182/blood.2020008609. Blood. 2021. PMID: 33512465 Free article. Clinical Trial. No abstract available.
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
Fürstenau M, Weiss J, Giza A, Franzen F, Robrecht S, Fink AM, Fischer K, Schneider C, Tausch E, Stilgenbauer S, Ritgen M, Schilhabel A, Brüggemann M, Eichhorst B, Hallek M, Cramer P. Fürstenau M, et al. Among authors: weiss j. Clin Cancer Res. 2022 Oct 3;28(19):4203-4211. doi: 10.1158/1078-0432.CCR-22-0433. Clin Cancer Res. 2022. PMID: 35594173 Clinical Trial.
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
Heger JM, Mattlener J, Schneider J, Gödel P, Sieg N, Ullrich F, Lewis R, Bucaciuc-Mracica T, Schwarz RF, Rueß D, Ruge MI, Montesinos-Rongen M, Deckert M, Blau T, Kutsch N, Balke-Want H, Weiss J, Becker K, Reinhardt HC, Hallek M, Borchmann P, von Tresckow B, Borchmann S. Heger JM, et al. Among authors: weiss j. Blood. 2024 Feb 8;143(6):522-534. doi: 10.1182/blood.2023022020. Blood. 2024. PMID: 37946299
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Fürstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, Stumpf J, Langerbeins P, Al-Sawaf O, Simon F, Fink AM, Schneider C, Tausch E, Schetelig J, Dreger P, Böttcher S, Fischer K, Kreuzer KA, Ritgen M, Schilhabel A, Brüggemann M, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P. Fürstenau M, et al. Among authors: weiss j. Blood. 2024 Jul 18;144(3):272-282. doi: 10.1182/blood.2023022730. Blood. 2024. PMID: 38620072 Clinical Trial.
5,544 results